Bryan, Garnier & Co acts as Sole Financial Advisor to HighLife on its €32 million Series B Fundraising
Context
HighLife is a medtech company focused on Transcatheter Mitral Valve Replacement (TMVR) for treating mitral regurgitation.
HighLife develops a minimally invasive prosthetic mitral valve implanted on a beating heart through the femoral vein and artery while preserving the native valve structure and respecting the surrounding anatomy.
Recognized as being best-in-class, the valve can be delivered trans-septally via the femoral vein in a reversible manner. The trans-septal route is the preferred route for both interventionists and patients as it avoids any surgery.
One of the few trans-septal valves in clinical development, HighLife competes with large international medtech companies and its technology offers differentiating features, notably: ease of use, self-centering and broad-fitting.
HighLife needed to raise funds to finance a US feasibility study and pivotal CE-marking study until 2021.
Transaction highlights
Bryan, Garnier & Co acted as Sole Financial Advisor to HighLife.
We conducted a broad, international private placement process targeting specialist and generalist funds across Europe, the US and China.
This €32m series B investment round was led by renowned American & European VC funds: USVP and Andera Partners, together with Sectoral Asset Management and Jose Calle Gordo, the company’s Chairman; Sofinnova, the major shareholder, significantly reinvested as well.
This transaction demonstrates our ability to support management teams throughout a demanding fundraising process and to access relevant investors that are today required to achieve larger size of fundraising.
In 2018 Bryan, Garnier & Co closed 19 transactions involving healthcare growth companies across Europe and the US. In particular we were advisors to Moderna for its pre-IPO round, bookrunners for the Medartis IPO on the SIX Swiss Stock Exchange, advised the sale of TxCell to Sangamo Therapeutics, led the follow-on offering of Celyad on NASDAQ and advised Montagu in its LBO on Maincare.
About Highlife
HighLife SAS was established in 2010 and is headquartered in Paris, France, with offices in Irvine (California). It is focused on the development of a novel transcatheter replacement system for treating mitral regurgitation. The technology aims at a beating heart procedure reducing trauma to the patients.
About Bryan, Garnier & Co
Bryan, Garnier & Co is a European, full service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich and New York. The firm is a member of the London Stock Exchange and Euronext.
Deal team
Olivier Garnier
Managing Partner
Healthcare Investment Banking
T: +44 207 332 2520
Sandrine Cailleteau
Managing Director
Healthcare Investment Banking
T: +33 1 56 68 75 26
Romain Ellul
Vice-President
Healthcare Investment Banking
T: +33 1 56 68 75 51
Rémi Negre
Analyst
Healthcare Investment Banking
T: +33 1 70 36 57 48
In the News
-
Bryan, Garnier & Co acts as Sole Financial Advisor to IK Investment Partners on its acquisition of Recocash
-
Bryan, Garnier & Co acts as Sole Financial Advisor to the Belgian consultancy firm Intys on its equity investment from Omnes
-
Bryan, Garnier & Co acts as Sole Financial Advisor to the audio tech company Arturia on its capital reorganisation led by EMZ Partners
-
Bryan, Garnier & Co acts as Sole Financial Advisor to drone software leader Unifly on a €17 million capital raise
-
Bryan, Garnier & Co makes significant move into the Nordics with the acquisition of Beringer Finance